Cabozantinib and Nivolumab With or Without Ipilimumab May Be Effective in Genitourinary Cancers
Cabozantinib and nivolumab (CaboNivo) with or without ipilimumab (Ipi) demonstrated manageable safety profiles and durable clinical activity.
Diagnosis & Disease Information
Adoptive Cellular Immunotherapy Improves Survival in Resected NSCLC
Adoptive cellular immunotherapy has not been widely used for cancer treatment.
Nivolumab Plus HPV-16 Vaccine are Promising in HPV-16+ Cancers
Immune checkpoint inhibition may improve the efficacy of vaccine-induced T cells in incurable HPV genotype 16-positive cancer.
First-Line Dose-Dense Chemo Fails to Prolong PFS in Ovarian Cancer
First-line treatment failed to improve progression-free survival among women of European descent with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC).
Nivolumab plus RT and Temozolomide Tolerated in Glioblastoma
First-line nivolumab plus radiotherapy (RT) with or without temozolomide was tolerated by patients with glioblastoma.
Sarcoma Resection at Expert Centers Associated With Better Outcomes
Surgical resection of soft tissue or visceral sarcoma conducted at an expert center resulted in substantially better outcomes compared with nonexpert centers.
Benefit of Binimetinib Addition to Encorafenib Confirmed in Melanoma
Binimetinib a BRAF inhibitor, improved objective response rate (ORR) and progression-free survival (PFS) among patients with BRAF-mutant melanoma.
- Loading...
Loading...
Next post in ESMO 2017
Loading... 
Loading...